Eliem Therapeutics Other Operating Income or Expenses 2021-2024 | CLYM

Eliem Therapeutics other operating income or expenses from 2021 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
Eliem Therapeutics Annual Other Operating Income or Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
Eliem Therapeutics Quarterly Other Operating Income or Expenses
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.342B $0.000B
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
Stock Name Country Market Cap PE Ratio
Chesapeake Energy (EXE) United States $11.186B 28.69
Hammerson (HMSND) United Kingdom $2.121B 0.00
American Software (LGTY) United States $0.388B 29.97
Learn CW Investment (INV) United States $0.204B 0.00
Nicholas Financial (OMCC) United States $0.079B 0.00
ExcelFin Acquisition (BDMD) $0.033B 0.00
Caravelle Group (HTCO) Singapore $0.024B 0.00
Recruiter (NIXX) United States $0.007B 0.00